August 15, 2017 07:30 AM EDTUpdated 12:11 PM
Bioregnum
Opinion

Trump's re­newed broad­sides on drug pric­ing did­n't even dent bio­phar­ma this time

Late Mon­day Pres­i­dent Don­ald Trump took his sec­ond shot at Mer­ck CEO Ken Fra­zier. Clear­ly still ran­kled by Fra­zier’s de­ci­sion to re­sign from Trump’ …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times